TY - JOUR
T1 - Trastuzumab emtansine for the treatment of HER-2 positive carcinoma Ex-pleomorphic adenoma metastatic to the brain
T2 - A case report
AU - Hassanieh, Ihab
AU - Hilal, Lara
AU - Al Feghali, Karine A.
AU - Khalifeh, Ibrahim
AU - Youssef, Bassem
N1 - Publisher Copyright:
© 2018 Hassanieh, Hilal, Al Feghali, Khalifeh and Youssef.
PY - 2018/7/24
Y1 - 2018/7/24
N2 - Background: Carcinoma Ex-pleomorphic adenoma is a malignant transformation of the common benign neoplasm of the salivary glands, "pleomorphic adenoma." Only two cases were ever reported with brain metastases, with absence of good evidence guiding management of such cases. Case Presentation: A 61-year-old woman presenting with facial paralysis was found to have carcinoma ex-pleomorphic adenoma of the parotid gland. Twenty months after local treatment, she developed brain metastases, treated with whole brain radiation therapy. The patient then had progressive intracranial disease after the end of radiation therapy in addition to the appearance of liver metastases. Pathology showed overexpression of HER2, so she was treated with Trastuzumab Emtansine (TDM1). Follow-up imaging revealed significant decrease in the number and size of the metastatic brain lesions in keeping with a good response to TDM1 treatment. Conclusion: Prognosis of metastatic carcinoma ex-pleomorphic adenoma is very poor, and there is no clear management for such cases. We present a case of carcinoma ex-pleomorphic adenoma with brain and liver metastases with a very good response to TDM1 treatment.
AB - Background: Carcinoma Ex-pleomorphic adenoma is a malignant transformation of the common benign neoplasm of the salivary glands, "pleomorphic adenoma." Only two cases were ever reported with brain metastases, with absence of good evidence guiding management of such cases. Case Presentation: A 61-year-old woman presenting with facial paralysis was found to have carcinoma ex-pleomorphic adenoma of the parotid gland. Twenty months after local treatment, she developed brain metastases, treated with whole brain radiation therapy. The patient then had progressive intracranial disease after the end of radiation therapy in addition to the appearance of liver metastases. Pathology showed overexpression of HER2, so she was treated with Trastuzumab Emtansine (TDM1). Follow-up imaging revealed significant decrease in the number and size of the metastatic brain lesions in keeping with a good response to TDM1 treatment. Conclusion: Prognosis of metastatic carcinoma ex-pleomorphic adenoma is very poor, and there is no clear management for such cases. We present a case of carcinoma ex-pleomorphic adenoma with brain and liver metastases with a very good response to TDM1 treatment.
KW - Brain metastases
KW - Carcinoma ex-pleomorphic adenoma
KW - Radiotherapy
KW - Trastuzumab emtansine
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85050376848&partnerID=8YFLogxK
U2 - 10.3389/fonc.2018.00274
DO - 10.3389/fonc.2018.00274
M3 - Article
AN - SCOPUS:85050376848
SN - 2234-943X
VL - 8
JO - Frontiers in Oncology
JF - Frontiers in Oncology
IS - JUL
M1 - 274
ER -